A DNA logic gate with dual-anchored proximity aptamers for the accurate identification of circulating tumor cells

2020 ◽  
Vol 56 (51) ◽  
pp. 6961-6964
Author(s):  
Tianshu Chen ◽  
Xin Fu ◽  
Qianqian Zhang ◽  
Dongsheng Mao ◽  
Yuchen Song ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Signal Amplification ◽  
Logic Gate ◽  
Accurate Identification ◽  
Sensitive Analysis ◽  
Multiple Biomarkers

A DNA logic gate that integrate the recognition of multiple biomarkers with signal amplification was fabricated to achieve the accurate and sensitive analysis of circulating tumor cells (CTCs).

scholarly journals Aptamer-Conjugated Graphene Oxide Membranes for Highly Efficient Capture and Accurate Identification of Multiple Types of Circulating Tumor Cells

2015 ◽  
Vol 26 (2) ◽  
pp. 235-242 ◽  
Author(s):  
Bhanu Priya Viraka Nellore ◽  
Rajashekhar Kanchanapally ◽  
Avijit Pramanik ◽  
Sudarson Sekhar Sinha ◽  
Suhash Reddy Chavva ◽  
...  
Keyword(s):  
Graphene Oxide ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Accurate Identification ◽  
Highly Efficient ◽  
Oxide Membranes ◽  
Graphene Oxide Membranes

Chip-Based Nanostructured Sensors Enable Accurate Identification and Classification of Circulating Tumor Cells in Prostate Cancer Patient Blood Samples

2012 ◽  
Vol 85 (1) ◽  
pp. 398-403 ◽  
Author(s):  
Ivaylo Ivanov ◽  
Jessica Stojcic ◽  
Aleksandra Stanimirovic ◽  
Edward Sargent ◽  
Robert K. Nam ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patient ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Prostate Cancer Patient ◽  
Accurate Identification ◽  
Blood Samples ◽  
Nanostructured Sensors

scholarly journals An Immune–Magnetophoretic Device for the Selective and Precise Enrichment of Circulating Tumor Cells from Whole Blood

Micromachines ◽  
2020 ◽  
Vol 11 (6) ◽  
pp. 560
Author(s):  
Chaithanya Chelakkot ◽  
Jiyeon Ryu ◽  
Mi Young Kim ◽  
Jin-Soo Kim ◽  
Dohyeong Kim ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Whole Blood ◽  
Nsclc Patient ◽  
Clinical Progression ◽  
Mcf7 Cells ◽  
Cytokeratin 18 ◽  
Multiple Biomarkers ◽  
Tyrosine Protein Kinase ◽  
Nsclc Patients

Here, we validated the clinical utility of our previously developed microfluidic device, GenoCTC, which is based on bottom magnetophoresis, for the isolation of circulating tumor cells (CTCs) from patient whole blood. GenoCTC allowed 90% purity, 77% separation rate, and 80% recovery of circulating tumor cells at a 90 μL/min flow rate when tested on blood spiked with epithelial cell adhesion molecule (EpCAM)-positive Michigan Cancer Foundation-7 (MCF7) cells. Clinical studies were performed using blood samples from non-small cell lung cancer (NSCLC) patients. Varying numbers (2 to 114) of CTCs were found in each NSCLC patient, and serial assessment of CTCs showed that the CTC count correlated with the clinical progression of the disease. The applicability of GenoCTC to different cell surface biomarkers was also validated in a cholangiocarcinoma patient using anti-EPCAM, anti-vimentin, or anti-tyrosine protein kinase MET (c-MET) antibodies. After EPCAM-, vimentin-, or c-MET-positive cells were isolated, CTCs were identified and enumerated by immunocytochemistry using anti-cytokeratin 18 (CK18) and anti-CD45 antibodies. Furthermore, we checked the protein expression of PDL1 and c-MET in CTCs. A study in a cholangiocarcinoma patient showed that the number of CTCs varied depending on the biomarker used, indicating the importance of using multiple biomarkers for CTC isolation and enumeration.

scholarly journals Identification of Biomarkers for Prostate Cancer

2014 ◽  
Vol 6 (3) ◽  
pp. 123
Author(s):  
Anna Meiliana ◽  
Andi Wijaya
Keyword(s):  
Prostate Cancer ◽  
Treatment Response ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Digital Rectal Examination ◽  
Treatment Decision ◽  
Common Type ◽  
Non Invasive ◽  
Specific Mortality ◽  
Multiple Biomarkers

BACKGROUND: Prostate cancer (PCa) was the second most common type of cancer and the fifth leading cause of cancer-related death in men. The great challenge for physicians is being able to accurately predict PCa prognosis and treatment response in order to reduce PCa-specific mortality while avoiding overtreatment by identifying of when to intervene, and in which patients.CONTENT: Currently, PCa prognosis and treatment decision of PCa involved digital rectal examination, Prostate-Speciic Antigens (PSA), and subsequent biopsies for histopathological staging, known as Gleason score. However, each procedure has its shortcomings. Efforts to find a better clinically meaningful and non-invasive biomarkers still developed involving proteins, circulating tumor cells, nucleic acids, and the ‘omics' approaches.SUMMARY: Biomarkers for PCa will most likely be an assay employing multiple biomarkers in combination using protein and gene microarrays, containing markers that are differentially expressed in PCa.KEYWORDS: prostate cancer, PSA, biomarkers, nomograms, miRNA, proteomic, genomic, metabolomic

scholarly journals Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation

2016 ◽  
Vol 23 (3) ◽  
pp. 746-756 ◽  
Author(s):  
Jamie M. Sperger ◽  
Lindsay N. Strotman ◽  
Allison Welsh ◽  
Benjamin P. Casavant ◽  
Zachery Chalmers ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Integrated Analysis ◽  
Multiple Biomarkers

Near-Infrared Fluorescent Ag2S Nanodot-Based Signal Amplification for Efficient Detection of Circulating Tumor Cells

2018 ◽  
Vol 90 (11) ◽  
pp. 6702-6709 ◽  
Author(s):  
Caiping Ding ◽  
Cuiling Zhang ◽  
Xueyang Yin ◽  
Xuanyu Cao ◽  
Meifang Cai ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Signal Amplification ◽  
Near Infrared ◽  
Efficient Detection
Sign in / Sign up

Export Citation Format

Share Document